2018AHA科学声明_难治性高血压的检测，评估和管理 (1).pdf

AHA Scientific Statement Resistant Hypertension: Detection, Evaluation, and Management A Scientific Statement From the American Heart Association Robert M. Carey, MD, FAHA, Chair; David A. Calhoun, MD, FAHA, Vice Chair; George L. Bakris, MD, FAHA; Robert D. Brook, MD, FAHA; Stacie L. Daugherty, MD, MSPH; Cheryl R. Dennison-Himmelfarb, PhD, MSN, FAHA; Brent M. Egan, MD; John M. Flack, MD, MPH, FAHA; Samuel S. Gidding, MD, FAHA; Eric Judd, MD, MS; Daniel T. Lackland, DrPH, FAHA; Cheryl L. Laffer, MD, PhD, FAHA; Christopher Newton-Cheh, MD, MPH, FAHA; Steven M. Smith, PharmD, MPH, BCPS; Sandra J. Taler, MD, FAHA; Stephen C. Textor, MD, FAHA; Tanya N. Turan, MD, FAHA; William B. White, MD, FAHA; on behalf of the American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council Abstract—Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a long-acting calcium channel blocker, a blocker of the renin-angiotensin system (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. The antihypertensive drugs should be administered at maximum or maximally tolerated daily doses. RH also includes patients whose